Subject: Give CMS Your Comments on Provenge Access by Friday, April 29
Give CMS Your Comments on Provenge Access by Friday, April 29
Over the last 7 months, nearly 4,000 of you signed the petition to the Centers for Medicare and Medicaid Services (CMS) in support of Medicare access to FDA-approved prostate cancer treatments such as Provenge, a new immunotherapy treatment for advanced prostate cancer. Many of you made additional comments on the CMS website and/or attended the MEDCAC meeting on November 17, 2010 in Baltimore, MD.
Now, CMS is completing their National Coverage Analysis (NCA) for Provenge. They have issued a proposed decision memo stating Provenge is reasonable and necessary for patients who have asymptomatic or minimally systematic castrate-resistant disease and are on Medicare.
Thanks to all of you for your attention and timely action. This issue has generated the largest outpouring of voices from the Us TOO network EVER on ANY topic. Together, our voices have made a difference in support of FDA approval and CMS coverage of a new treatment option for men with advanced prostate cancer!
Please forward this email to others who you feel would support and take action today.